Startseite>>Signaling Pathways>> Stem Cell>> Smoothened>>PF-5274857

PF-5274857

Katalog-Nr.GC13280

PF-5274857 ist ein potenter, selektiver, oral aktiver und gehirngÄngiger Smo-Antagonist mit einem IC50 von 5,8 nM und einem Ki von 4,6 nM. PF-5274857 hat Potenzial fÜr die Erforschung von Tumorarten, einschließlich Hirntumoren und Hirnmetastasen, die durch einen aktivierten Hh-Weg ausgelÖst werden.

Products are for research use only. Not for human use. We do not sell to patients.

PF-5274857 Chemische Struktur

Cas No.: 1373615-35-0

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
123,00 $
Auf Lager
5mg
112,00 $
Auf Lager
10mg
154,00 $
Auf Lager
50mg
630,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PF-5274857 is an inhibitor of hedgehog (Hh) signaling pathway and is identified as a potent and selective antagonist of Smoothened (Smo) with an IC50 of 5.8 nM.

Smoothened, a G protein-coupled receptor, is a component of the hedgehog signaling pathway and is conserved from flies to humans. This protein is the molecular target of the teratogen cyclopamine. SMO can act as an oncogene and the activation of SMO mutations leads to unregulated activation of the hedgehog pathway and cancer.

In MEF cells, treatment of PF-5274857 completely blocked Shh-induced Hh pathway activity, which was measured by the transcriptional activity of Smo downstream gene Gli1.

In vivo, PF-5274857 showed anti-tumor activity in a mouse medulloblastoma model with IC50 of 8.9 nM. PF-5274857 also shows significant dose-dependent tumor growth inhibition (TGI) and induces tumor regression. In skin tissue, downregulation of Gli1 and Gli2 is also observed with a similar time course by PF-52748571.

Reference:
1.   Rohner A, Spilker ME, Lam JL, et al. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier. Molecular cancer therapeutics.2012;11(1):57-65.

Bewertungen

Review for PF-5274857

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF-5274857

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.